Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy
Launched by GERMAN CANCER RESEARCH CENTER · Nov 7, 2011
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • histologically confirmed primary breast cancer, stage I-III, after lumpectomy or mastectomy, indication for adjuvant radiotherapy
- • BMI: 18-40
- • ability to understand and follow the study protocol
- Exclusion Criteria:
- • contraindication for exercise
- • participation in the BEATE trial or another systematic resistance or relaxation training
About German Cancer Research Center
The German Cancer Research Center (DKFZ) is a leading biomedical research institution dedicated to advancing cancer research and its application in clinical settings. Located in Heidelberg, DKFZ conducts innovative studies aimed at understanding the complexities of cancer biology, developing novel therapeutic strategies, and improving patient outcomes. As a prominent clinical trial sponsor, the center collaborates with national and international partners to facilitate cutting-edge research, translating scientific discoveries into effective treatments. With a commitment to excellence and a multidisciplinary approach, DKFZ plays a pivotal role in the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Patients applied
Trial Officials
Karen Steindorf, Prof. Dr.
Principal Investigator
German Cancer Research Center
Karin Potthoff, Dr.
Principal Investigator
University Hospital Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials